FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

cafead

Administrator
Staff member
  • cafead   Aug 14, 2023 at 11:42: AM
via This week, the FDA is due to decide on four therapeutic applications, including one for Huntington’s disease and two for ultra-rare diseases.

article source